BACKGROUND: Autoantibody detection has been assessed as tool for the diagnosis and the definition of idiopathic inflammatory myopathies (IIM). The aim of the study was to characterize the autoantibody profiling of a cohort of Italian patients with IIM. METHODS: Sera of 53 adult patients with definite IIM, according to Bohan-Peter criteria, were tested for anti-nuclear autoantibodies (ANA), using indirect immunofluorescence (IIF) method, and for myositis-specific autoantibodies (MSAs) and myositis-associated autoantibodies (MAAs), using two new commercial immunodot assays. RESULTS: MSAs and/or MAAs were detected in 29 of 53 (54.7%) patients with IIM. Twenty-three patients (43.4%) were positive for at least one MSAs: 13 (24.5%) had anti-histidyl-tRNA synthetase autoantibodies (Jo1), 4 (7.5%) had other anti-aminoacyl-tRNA synthetases autoantibodies (anti-ARS), 1 (1.8%) had anti-transcription intermediary factor 1 gamma autoantibodies (anti-TIF1γ), 2 (3.7%) had anti-nuclear helicase protein Mi-2 autoantibodies (anti-Mi-2), 4 (7.5%) had anti-small ubiquitin like modifier activating enzyme heterodimer autoantibodies (anti-SAE). Moreover, 17 patients (32%) were positive for at least one MAAs. Coexisting MSAs and MAAs were observed in 9 of 53 (16.9%) patients, anti-Jo1/SS-A autoantibodies in most cases. Overall sensitivity of immunodot assays was 54.7%, the specificity was almost absolute. At cut-off value of 1:160, the sensitivity of ANA-IIF was 52.8%, increasing to 66% if cytoplasmatic fluorescence reaction was reported. Notably, two (5.7%) ANA-IIF negative patients had MSAs, detected only by immunodot assays. CONCLUSION: It was possible to identify MSAs otherwise undetectable because of the use of new assays. Immunodot can reveal MSAs even when IIF results are inconclusive or, in some cases, ANA negative.
BACKGROUND: Autoantibody detection has been assessed as tool for the diagnosis and the definition of idiopathic inflammatory myopathies (IIM). The aim of the study was to characterize the autoantibody profiling of a cohort of Italian patients with IIM. METHODS: Sera of 53 adult patients with definite IIM, according to Bohan-Peter criteria, were tested for anti-nuclear autoantibodies (ANA), using indirect immunofluorescence (IIF) method, and for myositis-specific autoantibodies (MSAs) and myositis-associated autoantibodies (MAAs), using two new commercial immunodot assays. RESULTS: MSAs and/or MAAs were detected in 29 of 53 (54.7%) patients with IIM. Twenty-three patients (43.4%) were positive for at least one MSAs: 13 (24.5%) had anti-histidyl-tRNA synthetase autoantibodies (Jo1), 4 (7.5%) had other anti-aminoacyl-tRNA synthetases autoantibodies (anti-ARS), 1 (1.8%) had anti-transcription intermediary factor 1 gamma autoantibodies (anti-TIF1γ), 2 (3.7%) had anti-nuclear helicase protein Mi-2 autoantibodies (anti-Mi-2), 4 (7.5%) had anti-small ubiquitin like modifier activating enzyme heterodimer autoantibodies (anti-SAE). Moreover, 17 patients (32%) were positive for at least one MAAs. Coexisting MSAs and MAAs were observed in 9 of 53 (16.9%) patients, anti-Jo1/SS-A autoantibodies in most cases. Overall sensitivity of immunodot assays was 54.7%, the specificity was almost absolute. At cut-off value of 1:160, the sensitivity of ANA-IIF was 52.8%, increasing to 66% if cytoplasmatic fluorescence reaction was reported. Notably, two (5.7%) ANA-IIF negative patients had MSAs, detected only by immunodot assays. CONCLUSION: It was possible to identify MSAs otherwise undetectable because of the use of new assays. Immunodot can reveal MSAs even when IIF results are inconclusive or, in some cases, ANA negative.
Authors: G J D Hengstman; L van Brenk; W T M Vree Egberts; E L van der Kooi; G F Borm; G W A M Padberg; W J van Venrooij; B G M van Engelen Journal: J Neurol Date: 2005-02-23 Impact factor: 4.849
Authors: Johan Rönnelid; Sevim Barbasso Helmers; Helena Storfors; Katarina Grip; Lars Rönnblom; Karin Franck-Larsson; Gunnel Nordmark; Ingrid E Lundberg Journal: Autoimmun Rev Date: 2009-03-11 Impact factor: 9.754
Authors: S Suzuki; T Satoh; S Sato; M Otomo; Y Hirayama; H Sato; M Kawai; T Ishihara; N Suzuki; M Kuwana Journal: Rheumatology (Oxford) Date: 2008-08-07 Impact factor: 7.580
Authors: O M Zack Howard; Hui Fang Dong; De Yang; Nina Raben; Kanneboyina Nagaraju; Antony Rosen; Livia Casciola-Rosen; Michael Härtlein; Michael Kron; David Yang; Kwabena Yiadom; Sunita Dwivedi; Paul H Plotz; Joost J Oppenheim Journal: J Exp Med Date: 2002-09-16 Impact factor: 14.307
Authors: Z Betteridge; S Tansley; G Shaddick; H Chinoy; R G Cooper; R P New; J B Lilleker; J Vencovsky; L Chazarain; K Danko; M Nagy-Vincze; L Bodoki; M Dastmalchi; L Ekholm; I E Lundberg; N McHugh Journal: J Autoimmun Date: 2019-04-13 Impact factor: 7.094
Authors: Michael Mahler; Zoe Betteridge; Chelsea Bentow; Michaelin Richards; Andrea Seaman; Hector Chinoy; Neil McHugh Journal: Front Immunol Date: 2019-04-30 Impact factor: 7.561
Authors: Michael Mahler; Kishore Malyavantham; Andrea Seaman; Chelsea Bentow; Ariadna Anunciacion-Llunell; María Teresa Sanz-Martínez; Laura Viñas-Gimenez; Albert Selva-O'Callaghan Journal: Diagnostics (Basel) Date: 2021-11-30